CELLINK/BICO $159M Rev Bioink Market $999M by 2032 ARPA-H PRINT $65M Federal Grant 3D Bioprinting $5.6B by 2033 Bioink CAGR 14.2% — Fastest Segment CollPlant × CELLINK $2.8B Breast Implant Market Organ-on-Chip $952M by 2030 FDAMA 3.0 Dec 16, 2025 48,000+ BICO Instruments 65 Countries 11,900+ Research Citations CELLINK/BICO $159M Rev Bioink Market $999M by 2032 ARPA-H PRINT $65M Federal Grant 3D Bioprinting $5.6B by 2033 Bioink CAGR 14.2% — Fastest Segment CollPlant × CELLINK $2.8B Breast Implant Market Organ-on-Chip $952M by 2030 FDAMA 3.0 Dec 16, 2025 48,000+ BICO Instruments 65 Countries 11,900+ Research Citations

Domain Investment Thesis

The Consumable Layer of a $5.6B Industry

3D bioinks are the recurring-revenue material that every bioprinter consumes. Like reagents in genomics or toner in printing — the razor needs blades. The global bioink market is the fastest-growing segment in bioprinting, and FDAMA 3.0 just made it mandatory.

$225M

Bioink Market 2024

Maximize Market Research

$999M

Bioink Market 2032

Maximize Market Research

20.48%

Bioink CAGR

2024–2032

48K+

Instruments Installed

BICO Group 2025

01 / Corporate Landscape

Who's Buying, Building, and Funding Bioinks

BICO Group (CELLINK)

World's first universal bioink. 48K+ instruments, 3,500 labs, 65 countries. Used by top 20 pharma. Nasdaq-listed.

$159M rev

3D Systems

NextGen Bioprinting Platform (May 2025). Basel point-of-care facial implant (March 2025). Organ-on-chip expansion.

$440M rev

Aspect Biosystems

Bioprinted tissue therapeutics. Proprietary bioink tech for organ-on-chip drug testing. Major pharma partnerships.

$100M+ raised

CollPlant Biotech

rhCollagen bioinks. CELLINK partnership for regenerative breast implants in $2.8B market. Plant-derived collagen.

Nasdaq: CLGN

TheWell Bioscience

VitroINK® — no crosslinking, no UV, no heat curing needed. Distributed by REGEMAT 3D. Feb 2025 launch.

Novel bioink

BIO INX

READYGEL INX gel-MA bioink for Readily3D volumetric printing. First commercial bioink for volumetric technology.

2025 launch

ARPA-H (US Gov)

PRINT program: $65M for bioprinted liver, kidney, heart constructs. Federal demand signal for advanced bioinks.

$65M grant

Generate:Biomedicines × Novartis

$1B deal marrying AI protein design with bioprinting scaffolds. Bioink formulation is a core deliverable.

$1B deal

02 / Bioink Applications

Every Application Requires the Material

Drug Discovery

Bioprinted tissue models for preclinical testing. Replaces animal models under FDAMA 3.0 mandate.

Organ-on-Chip

Bioink-fabricated tissue layers on microfluidic devices. $952M market by 2030. FDA-endorsed alternative.

Tissue Engineering

Functional vascular grafts, bone scaffolds, cartilage. Symvess: first FDA-cleared tissue-engineered vascular graft, Dec 2024.

Regenerative Implants

Patient-specific orthopedic implants. Point-of-care facial implant at Basel (March 2025). 33.9% of market.

Cosmetic Testing

Bioprinted skin models replacing animal testing. L'Oréal, Shiseido adopting bioink-based assays. Regulatory-driven adoption.

Personalized Medicine

Patient-derived tumor models for drug sensitivity screening. POSTECH: 90% viability on gastric-cancer constructs.